## Yingkai Li

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6711445/publications.pdf

Version: 2024-02-01

10 papers	208 citations	1307594 7 h-index	1372567 10 g-index
10 all docs	10 docs citations	10 times ranked	271 citing authors

#	Article	IF	CITATIONS
1	The clinical need for clustered AChR cell-based assay testing of seronegative MG. Journal of Neuroimmunology, 2022, 367, 577850.	2.3	9
2	Knowledge and perceptions of the $\langle scp \rangle COVID \langle scp \rangle \hat{a} \in \mathbb{R}^9$ pandemic among patients with myasthenia gravis. Muscle and Nerve, 2021, 63, 357-364.	2.2	13
3	Normative dataset for plasma cytokines in healthy human adults. Data in Brief, 2021, 35, 106857.	1.0	11
4	Cellular changes in eculizumab early responders with generalized myasthenia gravis. Clinical Immunology, 2021, 231, 108830.	3.2	4
5	COVID-19-associated risks and effects in myasthenia gravis (CARE-MG). Lancet Neurology, The, 2020, 19, 970-971.	10.2	85
6	Circulating Th $1/17$ cells serve as a biomarker of disease severity and a target for early intervention in AChR-MG patients. Clinical Immunology, 2020, 218, 108492.	3.2	7
7	Imbalance in T follicular helper cells producing IL-17 promotes pro-inflammatory responses in MuSK antibody positive myasthenia gravis. Journal of Neuroimmunology, 2020, 345, 577279.	2.3	17
8	Imbalance of the two main circulating dendritic cell subsets in patients with myasthenia gravis. Clinical Immunology, 2019, 205, 130-137.	3.2	5
9	Tacrolimus inhibits Th1 and Th17 responses in MuSK-antibody positive myasthenia gravis patients. Experimental Neurology, 2019, 312, 43-50.	4.1	23
10	Clinical Characteristics of Juvenile Myasthenia Gravis in Southern China. Frontiers in Neurology, 2018, 9, 77.	2.4	34